[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) disclosed a routine insider transaction in a Form 4 filing. On 24 June 2025, director Alison Moore received a stock option for 13,750 common shares at an exercise price of $1.61 per share. The option vests in full on the earlier of 24 June 2026 or the company’s 2026 annual shareholder meeting and expires on 23 June 2035. Following the grant, Moore beneficially owns 13,750 derivative securities, held directly. No shares were bought or sold in the open market, and there were no accompanying cash transactions.

The filing reflects standard director compensation and does not signal changes to Artiva’s operating outlook, capital structure, or near-term liquidity.

Insights

Securities Analyst

TL;DR: Routine director option grant; neutral for valuation.

The $1.61 strike sits close to Artiva’s recent trading range, suggesting the grant was priced at fair market value. With only 13,750 shares underlying, the potential dilutive effect is de-minimis (well below 0.1% of basic shares outstanding). The one-year cliff aligns director incentives but does not materially alter insider ownership or governance dynamics. No cash proceeds are realized until exercise, so the company’s cash runway remains unchanged. Overall, the event is non-impactful to near-term fundamentals.

Corporate Governance Expert

TL;DR: Standard equity compensation; governance unchanged.

The grant follows Nasdaq-typical practice for newly appointed or continuing independent directors. Vest-on-earlier-of date ensures alignment leading into the 2026 AGM without accelerating vesting. No 10b5-1 plan was indicated, and the transaction code “A” confirms an award rather than open-market purchase. From a governance standpoint, there are no red flags or unusual terms that would concern investors.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOORE ALISON

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$1.61	06/24/2025		A		13,750		(1)	06/23/2035	Common Stock	13,750	$0	13,750	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.

	/s/ Neha Krishnamohan, Attorney-in-Fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What derivative securities did Alison Moore receive from ARTV?

13,750 director stock options with a $1.61 exercise price, expiring 23 June 2035.

When do the options granted to Alison Moore vest?

They vest in full on 24 June 2026 or the date of the 2026 annual shareholder meeting, whichever is earlier.

What is the impact of this Form 4 on Artiva Biotherapeutics’ share count?

The grant is immaterial; 13,750 options represent well under 0.1% of shares outstanding.

Did the insider buy or sell any ARTV common stock?

No. The filing only records an option grant; no common shares were bought or sold.

Does this filing indicate use of a Rule 10b5-1 trading plan?

The box for a Rule 10b5-1 plan was not checked; the transaction was a straightforward equity award.